Vertex Pharmaceuticals Incorporated (ETR:VX1)
Germany · Delayed Price · Currency is EUR | Market Cap | 98.20B -13.5% |
| Revenue (ttm) | 10.60B +10.1% |
| Net Income | 3.76B |
| EPS | 14.62 |
| Shares Out | n/a |
| PE Ratio | 26.10 |
| Forward PE | 22.62 |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 278 |
| Average Volume | 61 |
| Open | 384.80 |
| Previous Close | 383.35 |
| Day's Range | 381.30 - 385.90 |
| 52-Week Range | 312.65 - 433.25 |
| Beta | 0.46 |
| RSI | 61.17 |
| Earnings Date | May 4, 2026 |
About Vertex Pharmaceuticals
Vertex Pharmaceuticals Incorporated operates as a biotechnology company in the United States, Europe, and internationally. The company offers transformative medicines for people with serious diseases with a focus on specialty markets, such as cystic fibrosis (CF), sickle cell disease (SCD), transfusion dependent beta thalassemia (TDT), and acute pain. It markets TRIKAFTA/KAFTRIO for people with CF with at least one F508del mutation for 2 years of age and older; ALYFTREK for the treatment for people with CF 6 years of age and older; SYMDEKO/SYMK... [Read more]
News
Vertex to Participate in Upcoming May Investor Conferences
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced management participation in two upcoming investor conferences. Charlie Wagner, Chief Operating and Financial...
Vertex Pharmaceuticals price target raised to $615 from $607 at Barclays
Barclays raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $615 from $607 and keeps an Overweight rating on the shares.
Vertex Pharmaceuticals announces Casgevy reimbursement agreement
Vertex Pharmaceuticals (VRTX) Incorporated announced that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therapy, CASGEVY. This agreement secures sust...
Vertex Announces CASGEVY® Reimbursement Agreement for the Treatment of Sickle Cell Disease and Transfusion-Dependent Beta Thalassemia in Germany
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that a reimbursement agreement was signed with the GKV-Spitzenverband for its CRISPR/Cas9 gene-edited therap...
Vertex Pharmaceuticals price target raised to $616 from $612 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $616 from $612 and keeps an Overweight rating on the shares. Q1 results were “uneventful” and FY26 guidance…
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $543 from $541 and keeps an Outperform rating on the shares. Shares have been weak…
Vertex Pharmaceuticals price target lowered to $436 from $437 at Canaccord
Canaccord lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $436 from $437 and keeps a Hold rating on the shares. The firm said they reported a slight top-line…
Vertex Pharmaceuticals price target lowered to $572 from $577 at Bernstein
Bernstein lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $572 from $577 and keeps an Outperform rating on the shares. The firm notes revenue was in line while…
Moderna updates on Cystic Fibrosis collaboration with Vertex Pharmaceuticals
The company states: “Today, Vertex (VRTX) announced that it has decided to discontinue the Phase 1/2 study of the investigational inhaled CFTR mRNA candidate for cystic fibrosis, VX-522. Despite exten...
Vertex Pharmaceuticals Earnings Call Transcript: Q1 2026
Q1 2026 revenue rose 8% year-over-year to $2.99B, with strong growth in CF and new products like ALYFTREK, CASGEVY, and JOURNAVX. Robust R&D and commercial execution support 2026 guidance of $12.95–$13.1B revenue and over $500M from non-CF products.
Vertex Pharmaceuticals reports Q1 EPS $4.02, consensus $4.31
Reports Q1 revenue $2.99B, consensus $3.00B. “Vertex is off to a strong start in 2026, driven by leadership in cystic fibrosis; growth in sickle cell disease, beta thalassemia, and acute…
Vertex Pharmaceuticals affirms FY26 revenue $12.95B-$13.1B, consensus $13.05B
16:02 EDT Vertex Pharmaceuticals (VRTX) affirms FY26 revenue $12.95B-$13.1B, consensus $13.05B
Vertex tops profit estimates as sales of new cystic fibrosis drug surge
Vertex Pharmaceuticals on Monday beat Wall Street estimates for first-quarter adjusted profit, helped by a near eight-fold surge in sales of its new cystic fibrosis treatment.
Vertex Reports First Quarter 2026 Financial Results
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today reported consolidated financial results for the first quarter ended March 31, 2026, and reiterated its full year 2026 ...
Options Volatility and Implied Earnings Moves Today, May 04, 2026
Today, several major companies are expected to report earnings: ON Semiconductor (ON), Transocean (RIG), Vertex Pharmaceuticals (VRTX), Diamondback (FANG), Norwegian Cruise Line (NCLH), Innovative Ind...
Vertex Pharmaceuticals price target lowered to $437 from $441 at Canaccord
Canaccord lowered the firm’s price target on Vertex Pharmaceuticals (VRTX) to $437 from $441 and keeps a Hold rating on the shares. The firm updated its model ahead of Q1…
Vertex Pharmaceuticals price target raised to $612 from $596 at Morgan Stanley
Morgan Stanley raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $612 from $596 and keeps an Overweight rating on the shares. The firm adjusted models among its biopharma…
Vertex Pharmaceuticals price target raised to $543 from $541 at RBC Capital
RBC Capital analyst Brian Abrahams raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $543 from $541 and keeps an Outperform rating on the shares as part of the…
Vertex to Announce First Quarter 2026 Financial Results on May 4th
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) will report its first quarter 2026 financial results on Monday, May 4, 2026, after the financial markets close. The company ...
Vertex Announces US FDA Approval for Label Extensions of ALYFTREK® and TRIKAFTA®, Expanding Availability of These Medicines to ~95% of All People With CF in the United States
BOSTON--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) today announced the U.S. Food and Drug Administration (FDA) has approved expanded use of ALYFTREK® (vanzacaftor/tezacaftor/i...
TrumpRx lists many medicines at prices higher than paid in UK
U.S. President Donald Trump pledged to make prescription drugs cheaper for Americans than anywhere in the world, but his TrumpRx.gov website is not delivering across the board lower prices than those ...
Vertex Pharmaceuticals Transcript: Barclays 28th Annual Global Healthcare Conference
Diversification beyond cystic fibrosis is driving growth, with strong launches in sickle cell, beta thalassemia, and acute pain. Pivotal phase III data for povetacicept in IgAN show best-in-class efficacy and safety, with regulatory submission imminent. JOURNAVX and ALYFTREK are fueling commercial momentum.
This Pharmaceutical Stock Is Leading the S&P 500 Higher Tuesday, After 'Remarkable' Trial Results
Vertex Pharmaceuticals (VRTX) shares are soaring after the company said it achieved "remarkable" results from a new clinical trial.
Vertex passes key test In quest to treat kidney diseases
Vertex Pharmaceuticals said its drug for a rare kidney condition succeeded in a Phase 3 trial. The drug, povetacicept, is a central piece of the company's plan to expand into kidney disease.